NCT03357757 - Avelumab With Valproic Acid in Virus-associated Cancer | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

February 7, 2018

Primary Completion Date

March 30, 2022

Study Completion Date

March 31, 2025

Conditions

Cancer That is Associated With a Chronic Viral Infectionp16 Positive SCCHNSquamous Cell Carcinoma of the Cervixp16 Positive Squamous Cell Carcinoma of the Vagina or Vulvap16 Positive Squamous Cell Carcinoma of the Penisp16 Positive Squamous Cell Carcinoma of the Anus or Anal CanalEBER Positive NPCEBER Positive Hodgkins and Non-hodgkins Lymphona

Interventions

DRUG

Valproic Acid

The target serum level for VPA will be between 75 and 100 mcg/mL checked every 2 weeks for the first 6 cycles.

BIOLOGICAL

Avelumab

10 mg/kg IV

Trial Locations (1)

T6G 1Z2

Cross Cancer Institute, Edmonton